Analysts See $0.50 EPS for Anika Therapeutics Inc (ANIK)

July 17, 2017 - By Clifton Ray

 Analysts See $0.50 EPS for Anika Therapeutics Inc (ANIK)
Investors sentiment decreased to 1.01 in 2016 Q4. Its down 0.25, from 1.26 in 2016Q3. It dropped, as 17 investors sold Anika Therapeutics Inc shares while 53 reduced holdings. 20 funds opened positions while 51 raised stakes. 10.86 million shares or 0.92% less from 10.97 million shares in 2016Q3 were reported.
Calvert Investment Mngmt Inc holds 61,974 shares. Int Group Inc reported 10,411 shares. Northern has 0% invested in Anika Therapeutics Inc (NASDAQ:ANIK). Stifel Fincl Corporation reported 13,595 shares stake. Sg Americas Lc reported 3,163 shares. Susquehanna International Limited Liability Partnership invested 0% of its portfolio in Anika Therapeutics Inc (NASDAQ:ANIK). 59,234 are held by Fisher Asset Mgmt Ltd Liability Company. Rhumbline Advisers reported 19,455 shares. Jpmorgan Chase Co reported 0% stake. State Street holds 0% or 316,791 shares. First Citizens Bancorp Trust invested in 4,999 shares or 0.03% of the stock. Hl Limited holds 53,932 shares. State Of Tennessee Treasury Department invested in 11,778 shares. Geode Mngmt Ltd Liability Co has invested 0% in Anika Therapeutics Inc (NASDAQ:ANIK). Eaton Vance Mngmt owns 6,013 shares or 0% of their US portfolio.

Since February 22, 2017, it had 0 insider purchases, and 3 insider sales for $833,696 activity. Cheung Sylvia sold $196,096 worth of stock. Another trade for 2,635 shares valued at $129,326 was sold by LAND RAYMOND J.

Wall Street await Anika Therapeutics Inc (NASDAQ:ANIK) to release earnings on July, 26. Analysts forecast earnings per share of $0.50, down exactly $0.07 or 12.28 % from 2014’s $0.57 EPS. The expected ANIK’s profit could reach $7.32 million giving the stock 23.24 P/E in the case that $0.50 earnings per share is reported. After posting $0.37 EPS for the previous quarter, Anika Therapeutics Inc’s analysts now forecast 35.14 % EPS growth. The stock increased 0.76% or $0.35 during the last trading session, reaching $46.47. About 75,267 shares traded. Anika Therapeutics Inc (NASDAQ:ANIK) has risen 4.53% since July 18, 2016 and is uptrending. It has underperformed by 12.17% the S&P500.

Anika Therapeutics Inc (NASDAQ:ANIK) Ratings Coverage

Among 3 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Anika Therapeutics had 6 analyst reports since July 30, 2015 according to SRatingsIntel. Northland Capital downgraded the shares of ANIK in report on Wednesday, April 27 to “Market Perform” rating. Barrington Research initiated the shares of ANIK in report on Monday, October 12 with “Outperform” rating. The rating was upgraded by Zacks on Wednesday, August 26 to “Hold”. The firm earned “Equal Weight” rating on Friday, August 28 by First Analysis. The rating was maintained by Northland Capital with “Outperform” on Thursday, July 30. Northland Capital maintained Anika Therapeutics Inc (NASDAQ:ANIK) rating on Friday, February 26. Northland Capital has “Outperform” rating and $50 target.

Anika Therapeutics, Inc. is an orthopedic medicines company. The company has market cap of $680.26 million. The Firm is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid technology. It has a 22.46 P/E ratio. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA scaffold to aid cartilage repair and regeneration.

More notable recent Anika Therapeutics Inc (NASDAQ:ANIK) news were published by: which released: “Anika Announces Publication of Phase III Data Demonstrating the Efficacy and …” on May 22, 2017, also with their article: “4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings” published on July 17, 2017, published: “Anika Announces $5 Million Milestone Payment from US Commercial Sales of MONOVISC” on July 17, 2017. More interesting news about Anika Therapeutics Inc (NASDAQ:ANIK) were released by: and their article: “Anika Therapeutics, Inc., (Nasdaq: ANIK) to Ring The Nasdaq Stock Market …” published on February 27, 2017 as well as‘s news article titled: “Anika Therapeutics launches supplemental late-stage study of CINGAL for …” with publication date: May 25, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.